Fig. 5From: Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trialCorrelation between observed patient-reported outcomes and disease activity scores at Week 24Back to article page